Join to view full profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3779
Dr. Stover is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2015- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2009 - 2011
Harvard Medical SchoolClass of 2009
Certifications & Licensure
MA State Medical License 2013 - 2028
VT State Medical License 2022 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
- CMS Meaningful Use Stage 1 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2017
Clinical Trials
- Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer Start of enrollment: 2022 Nov 01
Publications & Presentations
PubMed
- Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography ra...Lauren Roller, Ningxuan Zhou, Isha Atre, Niya Xiong, Jiafei Li
Gynecologic Oncology. 2026-08-01 - Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial.Rebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, Martin Hayes, Madeline Polak
Nature Communications. 2026-03-26 - 9 citationsThe RAS-MEK-ERK pathway in low-grade serous ovarian cancer.Elizabeth H Stover, Elizabeth K Lee, Geoffrey I Shapiro, Joan S Brugge, Ursula A Matulonis
Gynecologic Oncology. 2025-09-01
Press Mentions
Twitter: Dr Toni Choueiri – FDA Approve Pembrolizumab Top Tweet Q4 2021November 4th, 2021
Nation’s Leading Cancer Hospital Is Running Out of MasksMarch 17th, 2020
Grant Support
- The roles of anti-apoptotic proteins BCL-XL and MCL1 in mediating survival of high-grade serous ovarian cancer following drug-induced DNA damageDANA-FARBER CANCER INST2019–2025
- The roles of anti-apoptotic proteins BCL-XL and MCL1 in mediating survival of high-grade serous ovarian cancer following drug-induced DNA damageDANA-FARBER CANCER INST2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
